HB1796 would reauthorize the sickle cell disease prevention and treatment demonstration program under the Public Health Service Act, and broaden its scope to explicitly include the prevention and treatment of complications of sickle cell disease and other heritable blood disorders. The bill also changes procurement options by allowing grants and cooperative agreements in addition to contracts, and increases the program’s annual funding.
A Sense of Congress urges further research into the causes and cures of heritable blood disorders.
In short, the bill commits federal resources to a more expansive, long-term effort on sickle cell disease and related conditions, with a stronger emphasis on managing complications and supporting research.If enacted, the program would operate with broader partnerships and higher annual funding from 2025 through 2029, signaling a more sustained federal role in surveillance, prevention, and treatment.
At a Glance
What It Does
Amends Section 1106(b) to broaden scope: adds treatment of complications to sickle cell disease and permits grants or cooperative agreements alongside contracts; increases authorized funding.
Who It Affects
Federal health programs, grantees and contractors, academic medical centers, state and local health departments, and healthcare providers involved in sickle cell care.
Why It Matters
Sets a broader, longer-term federal commitment to understanding and treating sickle cell disease and related disorders, with a stronger emphasis on complications and research.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill reauthorizes the sickle cell disease prevention and treatment demonstration program under the Public Health Service Act and expands its scope. It explicitly covers the prevention and treatment of complications arising from sickle cell disease and extends consideration to other heritable blood disorders.
The bill also broadens how the program can operate by allowing grants and cooperative agreements in addition to traditional contracts. Funding is increased to $8.205 million per year for fiscal years 2025 through 2029, reflecting a more expansive federal commitment.
A Sense of Congress section urges more research to understand the causes of these disorders and to pursue cures, which underscores a longer-term research agenda beyond the immediate demonstration program. The net effect is a more robust, multi-year federal effort intended to improve care delivery, surveillance, and scientific understanding of sickle cell disease and related conditions.Implementation would involve agencies within HHS coordinating with a range of grantees, including academic medical centers and community health partners, to fund studies, develop best practices, and support direct patient care focused on complications as well as disease management.
The Five Things You Need to Know
The bill broadens the program to include prevention and treatment of complications of sickle cell disease.
It allows grants or cooperative agreements in addition to contracts for program activities.
Annual funding is increased to $8.205 million for FY2025–FY2029.
The Sense of Congress urges expanded research into causes and cures for heritable blood disorders.
The title and text reflect an emphasis on sickle cell disease and related conditions under a broader public health framework.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Scope expanded to include complications
The amendment replaces the phrase “prevention and treatment of sickle cell disease” with “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease.” This expands the program’s focus from disease management to addressing the broader range of health issues that arise from complications, which could affect how services are designed and delivered, as well as what outcomes are measured.
Broadened scope for complications
Similar to paragraph (1), this change ensures that prevention and treatment efforts explicitly include complications of sickle cell disease. It signals an integrated care approach, potentially increasing the number of activities eligible for funding and collaboration with clinical and public health partners.
Procurement broadened (grants and cooperative agreements)
Subparagraph (A) now authorizes grants to, or contracts or cooperative agreements with, entities, expanding beyond sole contracting. Subparagraph (B) adjusts references to “prevention and treatment” language to emphasize treatment plus prevention and complications. This broadening improves flexibility in partnering with research institutions and healthcare providers to implement the program.
Funding increase 2025–2029
The act substitutes the prior funding level ($4,455,000 for 2019–2023) with $8,205,000 for each fiscal year 2025 through 2029. The uplift reflects a sustained federal investment intended to support expanded activities, longer-term surveillance, and broader care improvements within the demonstration program.
Sense of Congress on research
The bill includes a Sense of Congress that further research should be undertaken to expand understanding of the causes of heritable blood disorders and to pursue cures, including for sickle cell disease. While non-binding, this provision reinforces the overarching aim of linking demonstration activities to ongoing scientific inquiry.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with sickle cell disease and other heritable blood disorders gain expanded access to treatment and prevention of complications through the reauthorized program.
- Clinicians and care teams at demonstration sites receive broader resources, guidelines, and support to manage disease complications.
- Research institutions and public health researchers gain funding and scope to study causes, treatments, and potential cures.
- State and local health departments coordinating the program can align surveillance and services with expanded goals.
- Patient advocacy groups and community organizations can play a larger role in outreach, education, and program design.
Who Bears the Cost
- Federal taxpayers fund the increased annual appropriation through 2029.
- Federal agencies (e.g., HHS) incur administrative and oversight costs to implement and monitor the broader program.
- Grantees and partner institutions face additional reporting and compliance requirements to receive and manage funds.
- Healthcare systems and clinics participating in the program may incur administrative costs to adopt new guidelines and data collection.
- If the scope expands to other disorders, broader program administration and potential reallocations could affect other public health initiatives.
Key Issues
The Core Tension
Should resources be broadened to explicitly cover complications and other heritable disorders, potentially delivering greater real-world impact but increasing administrative complexity and cost, or should the program stay tightly focused on core sickle cell disease interventions to preserve budgetary predictability?
The amendments embed a broader scope for the sickle cell program and a higher funding level, but they also introduce complexity in governance and measurement. Expanding the range of activities to include complications and other heritable disorders may require new performance metrics, data systems, and cross-agency coordination.
The Sense of Congress strengthens the research agenda but does not bind future funding or policy changes, leaving implementation contingent on annual appropriations and administrative decisions. The shift toward grants and cooperative agreements adds flexibility but also demands robust monitoring to ensure outcomes align with program goals.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.